- Research article
- Open Access
Crystal structure of E. coli PRPP synthetase
BMC Structural Biology volume 19, Article number: 1 (2019)
Ribose-phosphate pyrophosphokinase (EC 126.96.36.199) is an enzyme that catalyzes the ATP-dependent conversion of ribose-5-phosphate to phosphoribosyl pyrophosphate. The reaction product is a key precursor for the biosynthesis of purine and pyrimidine nucleotides.
We report the 2.2 Å crystal structure of the E. coli ribose-phosphate pyrophosphobinase (EcKPRS). The protein has two type I phosphoribosyltransferase folds, related by 2-fold pseudosymmetry. The propeller-shaped homohexameric structure of KPRS is composed of a trimer of dimers, with the C-terminal domains forming the dimeric blades of the propeller and the N-terminal domains forming the hexameric core. The key, conserved active site residues are well-defined in the structure and positioned appropriately to bind substrates, adenosine monophosphate and ribose-5-phosphate. The allosteric site is also relatively well conserved but, in the EcKPRS structure, several residues from a flexible loop occupy the site where the allosteric modulator, adenosine diphosphate, is predicted to bind. The presence of the loop in the allosteric site may be an additional level of regulation, whereby low affinity molecules are precluded from binding.
Overall, this study details key structural features of an enzyme that catalyzes a critical step in nucleotide metabolism. This work provides a framework for future studies of this important protein and, as nucleotides are critical for viability, may serve as a foundation for the development of novel anti-bacterial drugs.
The metabolite phosphoribosylpyrophosphate (PRPP) is a building block for the biosynthesis of purine and pyrimidine nucleotides. Ribose-phosphate diphosphokinases or PRPP synthetases (EC 188.8.131.52, also called ribose-phosphate pyrophosphokinases) are a family of enzymes that catalyze the synthesis of PRPP from ATP and ribose-5-phosphate (R5P), yielding AMP as an additional product. This reaction effectively links the pentose phosphate pathway to the nucleotide salvage and de novo biosynthetic pathways as well as the biosynthesis of histidine, tryptophan, and pyridine nucleotide coenzymes [1, 2]. As PRPP is a metabolite that is required at all times in cells, the proper function of PRPP synthetases is essential for life. In humans, mutations that cause overactivity of this enzyme lead to excessive production of uric acid, which causes gout, developmental abnormalities and neurological impairment [3,4,5,6,7]. Three classes (I, II and III) of PRPP synthetases have been described and are differentiated based on phosphate requirements, allosteric regulatory mechanisms, and specificity [8,9,10,11,12,13]. Several crystal structures have been solved of PRPP synthetases, including those from B. subtilis (class I) , M. jannaschii (Class III), , B. pseudomallei (class I)  and human (class I) . The E. coli ribose-phosphate pyrophosphokinase (EcKPRS) is a class I PRPP synthetase with well-defined kinetics [9, 16,17,18]. Like other class I PRPP synthetases, EcKPRS is known to bind magnesium for efficient catalysis and makes use of an allosteric regulatory site [9, 17, 18]. Here, we report the X-ray crystal structure of EcKPRS, determined to 2.2 Å resolutionFootnote 1. The structure, determined by molecular replacement, confirms the hexameric organization of the protein and provides clear molecular details of both the active site and allosteric regulatory site. This work expands the repertoire of structurally characterized PRPP synthetases and will be a valuable tool to aid further detailed analyses of this important protein.
Protein expression, purification, crystallization and structure solution
The phosphoribosylpyrophosphate kinase from E. coli strain K12 was recombinantly expressed using E. coli BL21(DE3), purified used standard immobilized metal affinity chromatography and concentrated to 10 mg/mL for crystallization trials. Initial trials were conducted using sparse matrix screening with the hanging drop vapor diffusion method. After optimization of crystallization conditions, rod-shaped crystals of approximately 200 μm in length grew after 2 weeks. The crystals were frozen in the mother liquor and diffracted to approximately 2.22 Å. The final data set used for refinement was truncated at 2.22 (I/σ = 1.8, CC1/2 = 0.0.87, Rmerge = 0.42, and 95.1% completeness in the highest resolution shell, 2.22–2.26 Å). The space group was C2221 and there were three molecules in the asymmetric unit with a solvent content of 46% (Matthews number = 2.28). The structure was solved by molecular replacement using the PRPP synthetase from Burkholderia pseudomallei (PDB 3DAH) as the search model . After refinement converged, the final KPRS structure had an Rwork (working + test set) of 17.89% and an Rfree of 21.22%. A summary of data collection and refinement statistics is given in Table 1.
Structure of EcKPRS
As observed in other members of this protein family, EcKPRS has two α/β/α-sandwich domains related by two-fold pseudo-symmetry (Fig. 1). These two domains have the type I phosphoribosyltransferase fold and the protein belongs to the ribose phosphate pyrophosphokinase superfamily. The overall quaternary structure of EcKPRS, as observed in the crystal structure (Fig. 2a; composed of the 3 molecules in the asymmetric unit and 3 symmetry related molecules), predicted by the PISA Server , and confirmed by size exclusion chromatography (data not shown), is a hexamer. Two unit cells contribute to make the full biologically relevant oligomer. The three molecules in the asymmetric unit are structurally very similar (RMSD between chains A and B = 0.81 Å, between A and C = 0.85 Å, and between B and C = 0.79 Å). The hexamer assumes a propeller-like shape with 32 point symmetry. The C-terminal domain of each protomer dimerizes with one other C-terminal domain to form the blades of the propeller, while the N-terminal domains form the inner core of the structure (Fig. 2a). The inter-subunit interactions in EcKPRS are tight, with the two types of interface (the dimeric interface between two chains forming one blade of the propeller structure, between light purple and yellow chains or between light orange and green chains in Fig. 2a, and the interface between two chains from separate propeller blades, yellow and pink in Fig. 2a) burying approximately 1850 Å2 (12.7% of the total surface) and 1600 Å2 (11.0% of the total surface) of surface, respectively. The hexamer has a total surface exposed area of 59,260 Å2, and a total buried area of 26,980 Å2. Note that, in two of the three chains in the unit cell, a loop region spanning residues 196–203 is unstructured and could not be modeled. The corresponding region in the third chain (chain C in the EcKPRS structure), however, had clearly defined density and was well modeled. The three Ramachandran outliers in the structure are from Lys 242 in each of the three chains. The lysine residues are at a surface exposed region of the protein, away from either the active or allosteric sites. These lysine residues were clearly visible in the electron density and have orientations that are conserved in homologous PRPP synthetase structures (3DAH, 64% sequence identity, and 1DKR, 51% sequence identity) [8, 14].
Comparison of EcKPRS with other PRPP synthetase structures
The Type I phosphoribosyltransferase fold observed in the EcKPRS structure is highly similar to that observed for related phosphoribosyltransferases. The overall structure of the EcKPRS protomer superimposes well to that of the Burkholderia pseudomallei ribose-phosphate pyrophosphokinase structure (Fig. 2b; 3DAH, 64% sequence identity to EcKPRS), the Bacillus subtilis phosphoribosyl pyrophosphate synthetase (1DKR, 51% sequence identity to EcKPRS), and to the human phosphoribosyl pyrophosphate synthetase (2H06, 48% sequence identity to EcKPRS). The conserved active site residues, including H13, R96, Q97, D98 and R99 (Fig. 2c, numbering from EcKPRS) all adopt similar orientations. The only differences are the slight difference in orientation of the conserved glutamine residue (Fig. 2c, Q97 in EcKPRS) in the active site of B. pseudomallei with substrate bound (3DAH) and the arginine residue (R96 in EcKPRS) in the human structure (2H06). The movement of the glutamine residue is likely an induced fit to the AMP binding, leading to more favorable hydrogen bonding contacts between the glutamine and the 3’-OH of the AMP. The alternate conformation of the arginine residue in the human structure is positioned in an unoccupied region in the structure near where the phosphate moiety of the substrate binds. The flexibility of this residue, and its position in the active site, suggests that it too may move upon substrate binding to improve the protein-ligand interactions.
Active site of KPRS
The active site of EcKPRS is found between the two domains of the protomer (Fig. 2, AMP modeled in to mark active site position). Each active site, which accommodates the substrates AMP and R5P, is composed of residues from two chains of the hexamer (Fig. 3a). Based upon a superposition of EcKPRS with the B. pseudomallei structure, which shows the position of the nucleotide, the conserved active site residues that make contacts with the substrate can be clearly delineated. The purine ring is sandwiched between a phenylalanine residue (F35) from one chain and an arginine (R96) from a second chain (Fig. 3a). Additional polar contacts are made with the ribose and phosphate by residues Gln97, Asp98, Arg92, and His131 from one chain, and Asp37 and Glu39 from the neighboring chain (Fig. 3a). In our maps, we see two approximately globular regions of density consistent in size and shape with phosphate ions. One of these is positioned near where the β- or γ-phosphate of the nucleotide would be expected to be found (Fig. 3b). In addition, a small region of unexplained density is seen, in all three chains, in the position where the nucleotide would bind. While the density is not sufficient to accommodate the full nucleotide structure, it is possible that this density results from partial occupancy or some level of inherent flexibility of the nucleotide in the absence of the R5P co-substrate.
The R5P binding site is known to be made up of residues from the C-terminal region of a single chain. While there are not currently any type-I PRPP synthetase structures available with an R5P ligand bound, the R5P binding site can be inferred from comparison to other phosphoribosyltransferases [20, 21]. The amino acids that make up this active site, Asp224 through Lys231, are contiguously located on a binding loop (Fig. 3b). In the EcKPRS structure, a region of electron density consistent with a phosphate ion, was found to occupy the site believed to bind the phosphate of the R5P substrate, based upon superposition of EcKPRS with the B. subtilis and human PRPP synthetase structures [8, 15, 22]. This phosphate is in hydrogen bonding distance with the two backbone amides of Asp224, Thr225 and Gly226 as well as the side chain of Thr225. Placement of the R5P phosphate in this binding pocket would position the ribose ring in close proximity to the phosphates of the nucleotide co-substrate, ideal for efficient catalysis.
Allosteric site of EcKPRS
PRPP synthetases are known to be regulated by ADP and phosphate at an allosteric binding site distal from the active site [15, 17, 22]. Allosteric binding of ADP has been shown to be dependent on binding by Mg2+ and phosphate (Pi) [8, 15, 17, 23]. The allosteric inhibition by ADP appears to be competitive with the activation by Mg+ and Pi, suggesting that they bind to the same site [8, 17, 22]. Several conserved residues make up the allosteric site, which is located at an interface of three chains of the protein [8, 15]. The conserved residues that make up the putative allosteric site in EcKPRS are Gln136, Asp144, Ser308, Ser310, and Phe313 from one chain, Arg49 and Ser81 from a second chain, and several residues (including Arg102, Ser103, and Arg105) on a loop from a third chain (Fig. 4). In the structure of EcKPRS the loop containing Arg102-Arg105 occupies the space where the ADP molecule is purported to bind and an ion (modeled as chloride in EcKPRS) is located in place of where the β-phosphate would be. No other clashes with the protein are evident, suggesting that movement of this loop region would suffice to enable the protein to accommodate the ADP. This is consistent with previous reports that identified this region as a flexible loop [8, 15]. The observed position of the loop also suggests that this part of the structure can occupy the allosteric binding site in place of the native ligand. This suggests that loop binding at this site may act to regulate access by preventing low affinity molecules from binding.
PRPP synthetase is an important enzyme that produces a key metabolic intermediate necessary for the biosynthesis of purine and pyrimidine nucleotides. Dysfunction of this protein in humans can lead to severe neurodevelopmental disability. Herein, we provide the details of a 2.2 Å X-ray crystal structure of the PRPP synthetase from E. coli. Our structure reveals the molecular details of the active site of this hexameric protein and identifies the key residues for substrate binding and catalysis. In addition, the putative allosteric site and flexible loop that defines this region are well resolved in the structure. The flexible loop is found in a position that occupies key binding interactions for the allosteric regulator, thus suggesting a possible mechanism to prevent molecules with low affinity binding to this site. This work expands our understanding of this important class of enzyme and provides a structural framework for future studies.
Protein expression and purification
The E. coli (strain K12) ribose-phosphate pyrokinase (KPRS) gene (UniProt P0A717, NCBI NP_415727.1) was synthesized (GenScript) and cloned as an N-terminally His-tagged protein into the pTHT vector (a modified form of pET-28 with a Tobacco Etch Virus protease site in place of the thrombin site ) and expressed in E coli BL21(DE3) strain. Bacterial cultures were grown in LB broth supplemented with 50 mg/L kanamycin to an optical density at 600 nm of 0.7, at which point protein expression was induced with 0.1 m M isopropyl thiogalactopyranoside (IPTG). The induced cells were grown, with shaking, at 310 K for another four hours. The cultures were pelleted and the resulting pellets were stored at − 20 °C. For purification, freshly thawed cells were resuspended and lysed with lysis buffer (3 mL/g of pellet; 50 mM phosphate pH 7.6, 300 mM NaCl, 10 mM Imidazole). Cell lysates were passed over a pre-equilibrated (lysis buffer) Ni-NTA column (Qiagen). Non-specifically bound proteins were eluted with lysis buffer supplemented with 15 mM imidazole. KPRS protein was eluted using with lysis buffer supplemented with 250 mM imidazole. The protein was buffer exchanged using a 10DG column (BioRad) to storage buffer containing 10 mM Tris-HCl pH 7.6 and 30 mM NaCl, before concentrating the protein to a final concentration of 10 mg/mL as determined by absorbance on a NanoDrop (ThermoFisher). The protein was determined to be greater than 90% pure by SDS-PAGE. The final protein stock was aliquoted, flash frozen in liquid nitrogen, and stored at − 80 °C.
Crystallization and data collection
Initial sparse matrix screening was conducted for KPRS using the hanging-drop vapor diffusion method at 291 K. The optimized crystallization conditions contained equal volumes of the 10 mg/mL KPRS and a solution consisting of 0.2 M magnesium chloride hexahydrate, 0.1 M HEPES sodium pH 7.5, 30% w/v Polyethylene glycol 400, and 1 mM ADP. Note that, initial crystal screens were conducted using either 1 mM AMP, 1 mM ADP, or with neither AMP or ADP present. Crystals were briefly soaked in fresh crystallization solution prior to being flash frozen in liquid nitrogen. Data were collected at 100 K at the Advanced Photon Source on the North East Collaborative Access Team beamline 24-ID-C. Data were indexed, processed and scaled using HKL2000 . Data collection statistics are provided in Table 1.
Data processing, structure solution and refinement
Structures were solved by molecular replacement using MolRep version 11.02.08  with the PRPP synthetase from Burkholderia pseudomallei (PDB 3DAH)  as the search model. The models were refined using iterative rounds of manual model building with Coot , and restrained refinement with Refmac5 . After the refinement had converged, water molecules were added using Coot. The refinement statistics are provided in Table 1.
Additional software and online tools used
All of the structures shown in figures were made using PyMol version 1.3 (Schrodinger). The topology diagram was derived from results generated by the PDBSum server . The PDBe PISA server was used to determine the surface area of protein-protein interfaces . The MolProbity server  was used to validate structures and to generate a clashscore and MolProbity score. All figures were assembled using PhotoShop (Adobe).
Note that, during the preparation of this manuscript, a lower resolution (2.71 Å) structure of E. coli KPRS was released in the PDB (4S2U) without a corresponding literature discussion.
Jensen KF. Metabolism of nucleotides, nucleosides and nucleobases in micro-organisms. Munch-Petersen, Ed. London: Academic Press; 1983. pp 1–25.
Khorana HG, Fernandes JF, Kornberg A. Pyrophosphorylation of ribose 5-phosphate in the enzymatic synthesis of 5-phosphorylribose 1-pyrophosphate. J Biol Chem. 1958;230(2):941–8.
Becker MA, Losman MJ, Itkin P, Simkin PA. Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. J Lab Clin Med. 1982;99(4):495–511.
Becker MA, Losman MJ, Kim M. Mechanisms of accelerated purine nucleotide synthesis in human fibroblasts with superactive phosphoribosylpyrophosphate synthetases. J Biol Chem. 1987;262(12):5596–602.
Becker MA, Nosal JM, Switzer RL, Smith PR, Palella TD, Roessler BJ. Point mutations in PRPS1, the gene encoding the PRPP synthetase (PRS) 1 isoform, underlie X-linked PRS superactivity associated with purine nucleotide inhibitor-resistance. Adv Exp Med Biol. 1994;370:707–10.
Zoref E, De Vries A, Sperling O. Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts. J Clin Invest. 1975;56(5):1093–9.
Zoref E, Sivan O, Sperling O. Synthesis and metabolic fate of purine nucleotides in cultured fibroblasts from normal subjects and from purine overproducing mutants. Biochim Biophys Acta. 1978;521(2):452–8.
Eriksen TA, Kadziola A, Bentsen AK, Harlow KW, Larsen S. Structural basis for the function of Bacillus subtilis phosphoribosyl-pyrophosphate synthetase. Nat Struct Biol. 2000;7(4):303–8.
Hove-Jensen B, Harlow KW, King CJ, Switzer RL. Phosphoribosylpyrophosphate synthetase of Escherichia coli. Properties of the purified enzyme and primary structure of the prs gene. J Biol Chem. 1986;261(15):6765–71.
Kadziola A, Jepsen CH, Johansson E, McGuire J, Larsen S, Hove-Jensen B. Novel class III phosphoribosyl diphosphate synthase: structure and properties of the tetrameric, phosphate-activated, non-allosterically inhibited enzyme from Methanocaldococcus jannaschii. J Mol Biol. 2005;354(4):815–28.
Krath BN, Eriksen TA, Poulsen TS, Hove-Jensen B. Cloning and sequencing of cDNAs specifying a novel class of phosphoribosyl diphosphate synthase in Arabidopsis thaliana. Biochim Biophys Acta. 1999;1430(2):403–8.
Krath BN, Hove-Jensen B. Implications of secondary structure prediction and amino acid sequence comparison of class I and class II phosphoribosyl diphosphate synthases on catalysis, regulation, and quaternary structure. Protein Sci. 2001;10(11):2317–24.
Krath BN, Hove-Jensen B. Class II recombinant phosphoribosyl diphosphate synthase from spinach. Phosphate independence and diphosphoryl donor specificity. J Biol Chem. 2001;276(21):17851–6.
Baugh L, Gallagher LA, Patrapuvich R, Clifton MC, Gardberg AS, Edwards TE, Armour B, Begley DW, Dieterich SH, Dranow DM, Abendroth J, Fairman JW, Fox D 3rd, Staker BL, Phan I, Gillespie A, Choi R, Nakazawa-Hewitt S, Nguyen MT, Napuli A, Barrett L, Buchko GW, Stacy R, Myler PJ, Stewart LJ, Manoil C, Van Voorhis WC. Combining functional and structural genomics to sample the essential Burkholderia structome. PLoS One. 2013;8(1):e53851.
Li S, Lu Y, Peng B, Ding J. Crystal structure of human phosphoribosylpyrophosphate synthetase 1 reveals a novel allosteric site. Biochem J. 2007;401(1):39–47.
Bower SG, Harlow KW, Switzer RL, Hove-Jensen B. Characterization of the Escherichia coli prsA1-encoded mutant phosphoribosylpyrophosphate synthetase identifies a divalent cation-nucleotide binding site. J Biol Chem. 1989;264(17):10287–91.
Willemoes M, Hove-Jensen B, Larsen S. Steady state kinetic model for the binding of substrates and allosteric effectors to Escherichia coli phosphoribosyl-diphosphate synthase. J Biol Chem. 2000;275(45):35408–12.
Hove-Jensen B, Nygaard P. Phosphoribosylpyrophosphate synthetase of Escherichia coli, Identification of a mutant enzyme. Eur J Biochem. 1982;126(2):327–32.
Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372(3):774–97.
Krahn JM, Kim JH, Burns MR, Parry RJ, Zalkin H, Smith JL. Coupled formation of an amidotransferase interdomain ammonia channel and a phosphoribosyltransferase active site. Biochemistry. 1997;36(37):11061–8.
Scapin G, Ozturk DH, Grubmeyer C, Sacchettini JC. The crystal structure of the orotate phosphoribosyltransferase complexed with orotate and alpha-D-5-phosphoribosyl-1-pyrophosphate. Biochemistry. 1995;34(34):10744–54.
Eriksen TA, Kadziola A, Larsen S. Binding of cations in Bacillus subtilis phosphoribosyldiphosphate synthetase and their role in catalysis. Protein Sci. 2002;11(2):271–9.
Gibson KJ, Schubert KR, Switzer RL. Binding of the substrates and the allosteric inhibitor adenosine 5′-diphosphate to phosphoribosylpyrophosphate synthetase from Salmonella typhimurium. J Biol Chem. 1982;257(5):2391–6.
French JB, Ealick SE. Structural and mechanistic studies on Klebsiella pneumoniae 2-Oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase. J Biol Chem. 2010;285(46):35446–54.
Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–26.
Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):22–5.
Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 12 Pt 1):2126–32.
Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53(Pt 3):240–55.
de Beer TA, Berka K, Thornton JM, Laskowski RA. PDBsum additions. Nucleic Acids Res. 2014;42(Database issue):D292–6.
Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12–21.
The authors would like to acknowledge the assistance of Michael Lake, the Academic Research Director at Half Hollow Hills CSD.
JBF would like to acknowledge support from the National Science Foundation, award numbers 1455596 and 1750637, and the National Institutes of General Medical Sciences of the National Institutes of Health under Grant R35GM124898. This work is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P41 GM103403). The Pilatus 6 M detector on 24-ID-C beam line is funded by a NIH-ORIP HEI grant (S10 RR029205). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. The funding bodies were not involved in the design of the study, the collection, analysis or interpretation of the data, or writing the manuscript.
Availability of data and materials
The structural data for the reported KPRS structure is available in the protein data bank under code 6ASV.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Note that this work was carried out as part of a hybrid research/educational structural genomics pipeline hosted by the French lab at Stony Brook University. Using a crowdsourcing approach, the long-term goal of this program is to complete the structural assignment of all E. coli soluble proteins. The majority of the experiments and analysis are conducted by teams of undergraduate and high school level researchers, under the supervision of experienced crystallographers.
About this article
Cite this article
Zhou, W., Tsai, A., Dattmore, D.A. et al. Crystal structure of E. coli PRPP synthetase. BMC Struct Biol 19, 1 (2019). https://doi.org/10.1186/s12900-019-0100-4
- Nucleotide biosynthesis
- Phosphoribosyl pyrophosphate